Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Klaus Mross"'
Autor:
Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika Stern, Hendrik Gille, Laurent P Audoly, Max E Scheulen
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83232 (2013)
To report the nonrandomized first-in-human phase I trial of PRS-050, a novel, rationally engineered Anticalin based on human tear lipocalin that targets and antagonizes vascular endothelial growth factor A (VEGF-A).Patients with advanced solid tumors
Externí odkaz:
https://doaj.org/article/8cd061a0411d46768cf4d41e3c792632
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c80f812b75f509f0f95d8d4511a9475
https://doi.org/10.1158/1078-0432.c.6520397
https://doi.org/10.1158/1078-0432.c.6520397
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 41KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014dc1095ba0e6f04ade76edca1b1c5c
https://doi.org/10.1158/1078-0432.22445144.v1
https://doi.org/10.1158/1078-0432.22445144.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 52KB, Adverse events that led to permanent treatment discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0012c977ee3864af62502dce8eb60d34
https://doi.org/10.1158/1078-0432.22445141.v1
https://doi.org/10.1158/1078-0432.22445141.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 71KB, Best responses (maximum reduction in sum of longest diameter of target lesions from baseline) in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b2a7d07a67c24c91c0ee12990bc4bd
https://doi.org/10.1158/1078-0432.22445147
https://doi.org/10.1158/1078-0432.22445147
Autor:
Carol Peña, Daniel D. Von Hoff, Camille Granvil, Susanne Reschke, George R. Blumenschein, Isabelle Genvresse, Ferry A.L.M. Eskens, Klaus Mross, Donald A. Richards, Adam Skubala, Ramesh K. Ramanathan
Publikováno v:
Targeted Oncology, 15(2), 163-174. Springer Paris
Targeted Oncology
Targeted Oncology
Background Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. Objective This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b8f22f3210368cc26efa2cda323036
https://pure.eur.nl/en/publications/43a727cf-8f05-4b54-8524-de701a640591
https://pure.eur.nl/en/publications/43a727cf-8f05-4b54-8524-de701a640591
Autor:
Ferry A.L.M. Eskens, Daniel D. Von Hoff, Camille Granvil, Ramesh K. Ramanathan, Klaus Mross, Donald A. Richards, Isabelle Genvresse, Susanne Reschke, George R. Blumenschein, Carol Peña, Adam Skubala
Publikováno v:
Targeted Oncology. 15:803-803
Autor:
Klaus Mross
Publikováno v:
Info Onkologie. 18:32-34
Autor:
Klaus Mross
Publikováno v:
Info Onkologie. 18:28-30
Autor:
Klaus Mross
Publikováno v:
Info Onkologie. 18:22-24